01 Nov, EOD - Indian

SENSEX 79724.12 (0.42)

Nifty 50 24304.35 (0.41)

Nifty Bank 51673.9 (0.39)

Nifty IT 40433.65 (0.06)

Nifty Midcap 100 56496.05 (0.68)

Nifty Next 50 70400.75 (0.70)

Nifty Pharma 22807.15 (0.31)

Nifty Smallcap 100 18794.9 (1.03)

01 Nov, EOD - Global

NIKKEI 225 38053.67 (-2.63)

HANG SENG 20506.43 (0.93)

S&P 5771.25 (0.36)

Login/Signup
LOGIN HERE
Cancel

Rainbow Childrens Medicare Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 543524 | NSE Symbol : RAINBOW | ISIN : INE961O01016 | Industry : Healthcare |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
21-Oct-2024 27-Oct-2024 Quarterly Results Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2024 inter alia to consider and approve unaudited (Standalone & Consolidated) Financial results of the Company for the Quarter and Half Year ended September 30 2024 Results for the Quarter and Half year ended September 30, 2024 (As Per BSE Announcement Dated on 27.10.2024)
05-Aug-2024 13-Aug-2024 Quarterly Results Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the unaudited (Standalone & Consolidated) Financial results of the Company for the Quarter ended June 30 2024
12-May-2024 19-May-2024 Accounts Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2024 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results for the period ended March 31 2024 and to consider recommending Final Dividend if any. Recommendation of Final dividend of Rs. 3 per Equity Share for the Financial Year ended March 31, 2024 (As Per BSE Announcement Dated on 19.05.2024)
16-Jan-2024 24-Jan-2024 Quarterly Results Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2024 inter alia to consider and approve the Un-Audited (Standalone & Consolidated) Financial results of the Company for the quarter and nine months ended December 31 2023. Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2023 Appointment of Dr. Adarsh Kancharla as Non-Executive & Non-Independent Director of the Company Un-Audited Financial Results for the quarter and nine months ended December 31, 2023 (As per BSE Announcement Dated on 24/01/2024)
20-Oct-2023 30-Oct-2023 Quarterly Results Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2023 inter alia to consider and approve the Un-Audited (Standalone & Consolidated) Financial results of the Company for the Quarter and Half Year ended September 30 2023. Un-Audited Financial Results for the Quarter and Half Year ended September 30, 2023 Un-Audited Financial Results for the quarter and half year ended September 30, 2023 Re-appointment of Mr. Aluri Srinivasa Rao as an Independent Director of the Company (As Per BSE Announcement Dated on 30.10.2023)
31-Jul-2023 07-Aug-2023 Quarterly Results Rainbow Children''s Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 ,inter alia, to consider and approve Meeting of the Board of Directors is scheduled to be held on Monday, August 7, 2023 to inter-alia consider and approve the unaudited (Standalone & Consolidated) Financial results of the Company for the Quarter ended June 30, 2023. Please take note that the Board of Directors of the Company in their meeting held today i.e. August 7, 2023, approved un-Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter ended June 30, 2023. A copy of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. S. R. Batliboi & Associates LLP, Chartered Accountants, are attached herewith. Un-Audited Financial Results for the quarter ended June 30, 2023 Outcome of Board Meeting held on August 7, 2023 - Grant of Stock Units (As Per BSE Announcement Dated on 07.08.2023)
31-May-2023 31-May-2023 Change in Other Executives With reference to the captioned subject, please take note that Mr. R Gowrisankar, has resigned from the post of Chief Financial Officer (Key Managerial Personnel) of the Company due to personal reasons effective from May 31, 2023 (close of business hours). Mr. Gowrisankar shall now be serving his notice period and his last working day in the Company will be June 30, 2023. With reference to the captioned subject, please take note that upon recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors in their meeting held today i.e., May 31, 2023, approved appointment of Mr. Vikas Maheshwari as the Chief Financial Officer (Key Managerial Personnel) of the Company with effect from June 1, 2023. Pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find attached details of Key Managerial Personnel (KMP) of the Company authorised to determine materiality of an event or information.
05-May-2023 14-May-2023 Accounts Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2023 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31 2023 and to consider recommending Final Dividend if any on the Equity Shares of the Company for the Financial Year ended March 31 2023. Please take note that the Board of Directors of the Company in their meeting held today i.e. May 14, 2023, approved Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2023. A Copy of the signed Results along with Audit Reports issued by the Statutory Auditors M/s. BSR & Associates LLP and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations are attached herewith. This is in furtherance to the Company's communication dated May 14, 2023 regarding intimation of approval of Financial Results for the Quarter and Financial Year ended March 31, 2023. Please take note that due to some typographical error, the Results filed earlier carried an inadvertent linking error. Please further take note that it was a human error which was inadvertent and unintentional. We request you to please ignore the earlier filed results and take on record revised outcome of Board Meeting held on May 14, 2023 being submitted through this letter. Please take note that the Board of Directors of the Company in their meeting held today i.e. May 14, 2023, approved the following matters: 1. Audited Financial Results (Standalone and Consolidated) of the Company for Q4 and FY ended March 31, 2023. A Copy of the signed Results along with Audit Reports issued by the Statutory Auditors is attached herewith. 2. Re-appointment of Dr. Anil Dhawan as an Independent Director for another term of 5 consecutive years, commencing from August 30, 2023, subject to approval of the shareholders in the in the ensuing AGM. 3. Recommendation of final dividend of Rs 3/- per Equity Share (@ 30% on a face value of Rs 10/- per share) for the Financial Year ended March 31, 2023. 4. Convening of 25th AGM of the Company on Thursday, June 29, 2023 through Video Conferencing/ Other Audio Visual Means ('VC/OVAM'). 5. The Board has fixed June 22, 2023 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2022-23. Please take note that the Board of Directors of the Company in their meeting held today i.e. May 14, 2023, inter-alia recommended final dividend of Rs 3/- per Equity Share (@ 30% on a face value of Rs 10/- per share) for the Financial Year ended March 31, 2023. The dividend, if approved by the shareholders at the ensuing 25th Annual General Meeting ('AGM') will be dispatched/ credited within 30 days of the AGM. Appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 101049W/ E300004) as the Statutory Auditors of the Company, for a period of five years commencing from the conclusion of ensuing 25th Annual General Meeting till the conclusion of 30th Annual General Meeting of the Company, subject to approval of the Shareholders in the ensuing 25th Annual General Meeting (in place of the retiring Auditors M/s. BSR & Associates LLP, Chartered Accountants {ICAI Firm Reg. No. 116231W/W-100024}), in compliance with the mandatory rotation of auditors as per the provisions of the Companies Act, 2013. Please take note that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e. May 14, 2023, granted 2,75,000 (Two Lakhs and Seventy-Five Thousand) Stock Units ('Units') under the Stock Unit Plan 2023 to its eligible employees. The plan is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ['SEBI (SBEB & SE) Regulations, 2021']. Re-appointment of Dr. Anil Dhawan (DIN: 08191702) as an Independent Director for another term of 5 consecutive years, commencing from August 30, 2023, subject to approval of the shareholders in the ensuing 25th Annual General Meeting. Dr. Dhawan has confirmed that he is not debarred from holding the office of director by virtue of any Order of SEBI or any other authority. The requisite disclosures as per Regulation 30 of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as 'Annexure - A'. The Board of Directors at their meeting held today i.e., May 14, 2023, have, inter alia, approved convening of 25th AGM of the Company on Thursday, 29th June, 2023 through video conference or other audio-visual means. Please take note that the Board of Directors of the Company in their meeting held today i.e. May 14, 2023, inter-alia, considered and approved the following: 1. Appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 101049W/ E300004) as the Statutory Auditors of the Company. 2. Appointment of M/s. Deloitte Touche Tohmatsu India LLP as the Internal Auditors of the Company, for a period of two years i.e., For Financial Year 2023-24 & 2024-25. 3. Re-Appointment of M/s. Ravi & Subramanyam Company Secretaries as the Secretarial Auditors of the Company for the Financial Year 2023 - 24. 4. Re-Appointment of M/s. Lavanya & Associates acted as the Cost Auditors of the Company for the Financial Year 2023-24. (As Per BSE Announcement dated on 14.05.2023)
15-Apr-2023 15-Apr-2023 Change in Other Executives Please take note that, upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., April 15, 2023, approved appointment of Mr. Sanjeev Sukumaran as the Group Chief Operating Officer (Key Managerial Personnel) with effect from April 15, 2023.
18-Mar-2023 18-Mar-2023 Employee Stock Option This is to inform you that the Board of Directors of M/s. Rainbow Children's Medicare Limited ('the Company') in their meeting held today i.e., March 18, 2023, inter alia considered and approved, formulation of Employee Stock Unit Plan, viz., Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ('Stock Unit Plan 2023'/ 'Plan'), for grant of not exceeding 4,00,000 (Four Lakhs) Stock Units to Eligible Employees of the Company, as may be determined by the Nomination and Remuneration Committee in terms of the Plan, subject to approval of the shareholders and/ or such other regulatory/ statutory approvals as may be necessary. The requisite disclosure as per Regulation 30 of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as 'Annexure - A' to this letter.
01-Feb-2023 09-Feb-2023 Quarterly Results Rainbow Childrens Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve the Un-Audited (Standalone & Consolidated) Financial results of the Company for the Quarter and Nine Months ended December 31 2022. Please take note that the Board of Directors of the Company in their meeting held today i.e. February 9, 2023, approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended December 31, 2022. Copy of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP, are attached herewith. (As Per BSE Announcement Dated on 09/02/2023)
27-Oct-2022 03-Nov-2022 Quarterly Results Quarterly Results Rainbow Children''s Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Thursday, November 3, 2022 to inter-alia consider and approve the Un-Audited (Standalone & Consolidated) Financial results of the Company for the Quarter and Half Year ended September 30, 2022. (As Per BSE Announcement Dated on 26.10.2022) Please take note that the Board of Directors of the Company in their meeting held today i.e. November 3, 2022, approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2022. Copy of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith. (As per BSE Announcement Dated on 03/11/2022)
01-Aug-2022 08-Aug-2022 Quarterly Results Quarterly Results 1. The unaudited Standalone and Consolidated Financial Results ('Results') of the Company for the first Quarter ended June 30, 2022. Copies of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith. 2. Convening of 24th Annual General Meeting ('AGM') of the Company on Thursday, September 15, 2022 through Video Conferencing/ Other Audio Visual Means (VC/OVAM). 3. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021- 22 (if approved by the Shareholders at the ensuing AGM). 4. Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders at the ensuing AGM). The Board of Directors of Rainbow Children's Medicare Limited ('the Company') in their meeting held today i.e. August 8, 2022, has approved the Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM. The details of the reclassification of Authorised Share Capital is described below: 'Reclassification of Authorized Share Capital from INR. 150,00,00,000 divided into (a) 13,90,55,616 Equity Shares of INR 10/- each (b) 11,46,771 - Series A 0.0001% Compulsorily Convertible Preference Shares ('Series A CCPS') of INR. 48/- each and (c) 11,33,309 Series B 0.0001% Compulsorily Convertible Preference Shares ('Series B CCPS') of INR. 48/- to INR. 150,00,00,000 divided into 15,00,00,000 Equity Shares of INR 10/- each.' (As Per BSE Announcement Dated on 08/08/2022)
20-May-2022 27-May-2022 Accounts Final Dividend & Audited Results Please take note that the Board of Directors in their meeting held today i.e. May 27, 2022 Recommended final dividend of INR. 2.0/- per Equity Share (@ 20% on a face value of INR. 10/- per share) for the Financial Year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting ('AGM') will be dispatched/ credited within 30 days of the AGM and further information in this regard including record date etc. shall be submitted with the Stock Exchanges in due course. Dear Sir/ Madam, Please take note that the Board of Directors in their meeting held today i.e. May 27, 2022 approved following matters: 1. The Audited Standalone and Consolidated Financial Results ('Results') of the Company for the Quarter and Financial Year ended March 31, 2022. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith. 2. Recommendation of final dividend of INR. 2.0/- per Equity Share (@ 20% on a face value of INR. 10/- per share) for the Financial Year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting ('AGM') will be dispatched/ credited within 30 days of the AGM and further information in this regard including record date etc. shall be submitted with the Stock Exchanges in due course. (As per BSE Announcement Dated on 27/5/2022)
1